QuBeats Raises $15.0M Seed Round for Quantum Sensing

Fortell

Fortell is designing better hearing aids for life as it’s meant to be heard. Traditional hearing aids make everything louder but they don’t do enough to help the brain separate conversation from noise in the moments that matter. Fortell changes that. Our AI-powered hearing technology doesn’t just amplify, it clarifies. Fortell uses custom AI chips to help the brain decode speech in real time, lifting voices up above the chaos so people don’t just hear, they understand. Our mission is ambitious yet deeply personal: to restore effortless connection through better hearing. Every decision we make is grounded in cutting-edge science, human-centered design, and a commitment to improving lives at scale. We are backed by Thrive Capital, Valor Equity Partners, Founders Fund, Optum Ventures, Lux Capital, Vast Ventures, Good Friends, Positive Sum, Stonecroft, and Atreides Management. Our debut product is available now at Fortell Audiology on Park Avenue and 61st Street. We move fast, build with intention, and never lose sight of the people we’re building for. We’re bringing together exceptional minds in technology, science, design, and care–and we’re just getting started. We’re hiring. Join us as we bring clarity and connection back to life.

Euka AI

Top e-commerce brands use Euka to drive TikTok Shop sales. Produce winning content in partnership with trending creators, then multiply content with our suite of AI content generation tools.

Retham Technologies

Retham Technologies™ LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT). ​ HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputation, stroke and death. The diagnosis of HIT is challenging. A family of easy-to-run tests called PF4 ELISAs is performed in the hospital laboratory but have high false positive rates, i.e. many patients positive for antibodies to PF4:polyanion complexes do not have clinical HIT. A second test, the Serotonin release assay (SRA), is considered the “gold-standard” test for HIT; but, it is performed only at a handful of laboratories nationally on a small fraction of suspected cases due to technical complexity, cost and turnaround time concerns. Thus, >90% of HIT suspected patients are currently managed using PF4 ELISAs, and thousands of patients receive costly non-heparin anticoagulant therapy due to “false positive” diagnoses. These alternative anticoagulants have a worse bleeding risk profile relative to heparin often resulting in severe or fatal hemorrhage. Retham Technologies™ is developing HITDx™, an IVD assay for early and accurate near-patient HIT diagnosis that is expected to facilitate timely and appropriate therapy thereby leading to better outcomes.